AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02522559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spice Intervention
Description: Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
Study NCT04245059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-channel Transcranial direct current stimulation
Description: A commercial tDCS device will be use in this study. The device is a wireless multi-channel transcranial direct current stimulator that incorporates an 8-channel headcap for stimulation through gel electrodes or classic sponge electrodes. The device is integrated with a user interface for the configuration and monitoring of the stimulus parameters and a fast multifocal simulation of the tDCS electric field using an advanced brain model
Study NCT05343260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
Study NCT05343260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
Study NCT04069481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
Study NCT04069481 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation and Exercise
Description: One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
Study NCT04411693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone implant
Description: A sustained-release drug delivery system containing 0.7 mg of Dexamethasone. Implant is administered by intravitreal injection.
Study NCT04411693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: A single dose, 2mg, drug administered by intravitreal injection.
Study NCT01914601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh-King Vision
Description: laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
Study NCT01914601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King Vision-Macintosh
Description: laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
Study NCT03140280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freeze-Dried Black Raspberry Powder
Description: 25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
Study NCT04734743 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cystic fibrosis
Description: Evaluation of Upper Extremity Muscle Strength and Endurance, functional capacity, Respiratory Function and Quality of Life
Study NCT02713061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-850
Description: TAK-850 injection
Study NCT03240705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude journaling
Description: Gratitude journaling 3 times a week during surgical rotation
Study NCT00902928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00902928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: SC injection
Study NCT00663702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subcutaneous injection, 125 mg/mL, once weekly, 48 months
Study NCT03524716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit and Text Messages
Description: Physical activity tracker wristband and daily text messages delivered to the participants' phones.
Study NCT04316117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04316117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT00626990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
Study NCT04316117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03319498 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peppermint Oil Vapor
Description: 2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum.
Study NCT03319498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mineral Oil Vapor
Description: 2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum.
Study NCT01981616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab for intravenous infusion
Study NCT01981616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion
Study NCT01981616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hepatitis B vaccine
Study NCT01981616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Study NCT01981616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral cholera vaccine
Study NCT01981616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine
Study NCT01973881 — intervention group
Intervention type: PROCEDURE
Intervention: T1 Weighted MRI (magnetic resonance imaging)
Description: Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations.
Study NCT00525837 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fixed dose varenicline
Description: varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
Study NCT00525837 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: varenicline
Description: up to 1 mg twice daily
Study NCT02655003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME
Study NCT02655003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education-only intervention
Description: The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
Study NCT01208285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: 150 mg oral tablet
Study NCT00626990 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status is used for stratification at randomization.
Study NCT00626990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Prognostic factor analyses
Study NCT03040401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1, Ceplene® and Proleukin®
Description: Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study NCT03040401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2, Ceplene® and Proleukin®
Description: Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study NCT03040401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3, Ceplene® and Proleukin®
Description: Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2.
Study NCT00826553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
Study NCT00826553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GABA agonist
Description: Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
Study NCT00308945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost 0.004% (drug)
Description: local drop application
Study NCT00308945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005% (drug)
Description: local drop application
Study NCT02062138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous passive motion (CPM)
Description: standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
Study NCT02062138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled active motion (CAM I)
Description: Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
Study NCT02062138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled active motion (CAM II)
Description: Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
Study NCT04887649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 3 mg
Study NCT04887649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 4 cc of saline solution in epidural cateter in postpartum
Study NCT04887649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine 2 mg for epidural cateter in postpartum
Study NCT00747916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoSpray Ablation (TM) System
Description: Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
Study NCT00626990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
Study NCT00626990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Quality of Life analysis will also be used to assess neurological deterioration free progression
Study NCT00626990 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
Study NCT01440998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01157845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BreathID (Methacetin breath test)
Description: 13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
Study NCT04245969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: 448 kilohertz Capacitive Resistive Monopolar Radiofrequency stimulus
Description: 448kilohertz capacitive resistive monopolar radiofrequency will be applied on the shoulder and thoracic area
Study NCT04245969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham comparator
Description: A simulation of 448kilohertz capacitive resistive monopolar radiofrequency will be carried out to make believe the patient to be treated through this equipment.
Study NCT04245969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: These participants will be assessed at the same time than the rest of participants. They will not receive any kind of treatment.
Study NCT02669706 — intervention group
Intervention type: DRUG
Intervention: Pentamidine
Description: Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
Study NCT02100124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reproductive Life Planning (RLP)
Study NCT01440998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT01440998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01440998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02100124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive Action Planning
Study NCT02100124 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contraception information
Study NCT02100124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception information
Study NCT04454359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Study NCT04454359 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01278758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404, DMXAA or DXAA
Study NCT02172027 — intervention group
Intervention type: DEVICE
Intervention: Immunomagnetic Detection
Description: Analysis of pleural effusion through immunomagnetic detection device.
Study NCT04650737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single shot ESBP with dexmedtomidine
Description: Patients in this group will receive errector spine plane block with 30 ml bupivacaine 0.25% plus 1ml of 1µg/kg Dexmedetomidine
Study NCT04650737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continous ESPB
Description: Patients in this group will receive erector spine plane block with 30 ml bupivacaine 0.25%plus 1ml normal salinefollowed by continuous infusion of 8ml / hour of 0.125% bupivacaine for 24 hrs.
Study NCT01008410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide will be administered as per the dose and schedule specified in the respective arm.
Study NCT01008410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
Study NCT02988050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Remifentanil used for conscious sedation.
Study NCT02988050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Dexmedetomidine used for conscious sedation.
Study NCT02988050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Used for conscious sedation.
Study NCT02988050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Local anaesthetics
Study NCT02988050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: Local anaesthetic
Study NCT02988050 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epinephrine
Description: With local anaesthetic for skin infiltration.
Study NCT02349425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 7.5 and 50mg tablets administered orally
Study NCT02349425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for gefapixant)
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally
Study NCT03022253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liberal platelet transfusion
Description: Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~1. PDA closes or~2. A maximum of 120 hours after the point of randomisation
Study NCT03022253 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive platelet transfusion
Description: The investigators will transfuse platelets only if:~(i) Platelet count is \< 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count \< 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count \< 1, 00,000 per microliter and requires a neurosurgical procedure
Study NCT03022253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV
Study NCT03022253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV
Study NCT03022253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
Study NCT03022253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
Study NCT04359043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Description: MISC is an intervention that focuses on increasing the caregiving capacity of the caregiver by enhancing a set of emotional and cognitive components that collectively, sensitizes the caregiver to the emotional and cognitive needs of the child.
Study NCT04359043 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Treatment as Usual was delivered by community-based organization caseworkers. It consists of a nutritional curriculum of the same dosage and time commitment as the experimental condition, but with no caregiving component.
Study NCT03205397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child